A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
While blank-cheque mergers can net healthtechs a huge amount of capital, not all investors stay the course.
But a lacklustre pipeline could stoke the need for deals.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Novo moves into amyloidosis not long after Intellia made a splash here.
And four other potential targets that could make sense for the beleaguered group.
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.